Default Category
-
Merck: La administración de Vioxx (D)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S05Knowledge and CommunicationStarting at €5.74
-
Pfizer: Letter from the Chairman (B)
Simons, Robert L.; Rosenberg, KathrynCase HBS-110004-EAccounting and ControlThis case continues the story begun in "Pfizer: A Letter From The Chairman" (HBS No. 9-110-003), revealing the letter Chairman and CEO Jeff Kindler wrote for the 2008 Annual Report.Starting at €5.74
-
Pfizer: Letter from the Chairman (A) and (B), Teaching Note
Simons, Robert L.; Rosenberg, KathrynTeaching Note HBS-110067-EAccounting and ControlTeaching Note for 110003 and 110004.Starting at €0.00
-
Improving Worker Safety in the Era of Machine Learning: Practicum in Predictive Analytics, Teaching Note
Toffel, Michael W.; Levy, DanTeaching Note HBS-619071-EEconomicsTeaching note for case 618019.Starting at €0.00
-
Improving Worker Safety in the Era of Machine Learning: Practicum in Predictive Analytics, PowerPoint
Toffel, Michael W.; Levy, DanCase HBS-619718-EEconomicsSlides for case 618019.Starting at €8.20
-
Providing Pensions for the Poor: Targeting Cash Transfers for the Elderly in Mexico
Levy, Dan; Coarasa, JorgeCase HBS-HKS787-EWhen the Mexican Congress approved the country's 2007 budget, it included an appropriation of 8.5 billion pesos allocated to provide non-contributive pensions to senior citizens. President Felipe Calderon wanted to introduce eligibility criteria that would ensure the new federally-funded pensions would go to poor seniors that would otherwise lack the means to sustain themselves. This case puts the reader in the shoes of Calderon's advisor, asking...Starting at €8.20
-
Providing Pensions for the Poor: Targeting Cash Transfers for the Elderly in Mexico Teaching Note
Levy, Dan; Coarasa, JorgeTeaching Note HBS-HKS788-ETeaching Note for HKS787Starting at €0.00
-
Managing Vioxx (A) (Spanish version)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S02Strategy(B) evidence of life-threatening side effects, (C) decision options, (D) announcement to withdraw Vioxx, (E) reaction by patients, shareholders, media, and regulators, (F) Merck fights back, and (G) wrap-up. At the end of the case series, students may conclude that doing the right thing sometimes requires very hard choices.Starting at €8.20
-
Merck: La administración de Vioxx (B)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S03Knowledge and CommunicationStarting at €5.74
-
Merck: La administración de Vioxx (C)
Simons, Robert L.; Rosenberg, Kathryn; Kindred, NatalieCase HBS-111S04Knowledge and CommunicationStarting at €5.74